ReviewAdvanced drug delivery reviews2016
Stem cell-based therapies for HIV/AIDS.
Review in Advanced drug delivery reviews, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 43 citations in OpenAlex.
- From bench to bedside: stem cell therapy as a transformative approach against HIV.Molecular biology reports · 2026Review
- Chemokine receptor type-5: a key regulator of immunity, disease pathogenesis, and emerging therapeutic target.Inflammopharmacology · 2025Review
- Spotlight on the impact of viral infections on Hematopoietic Stem Cells (HSCs) with a focus on COVID-19 effects.Cell communication and signaling : CCS · 2023Review
- Engineered Zinc Finger Protein Targeting 2LTR Inhibits HIV Integration in Hematopoietic Stem and Progenitor Cell-Derived Macrophages: In Vitro Study.International journal of molecular sciences · 2022Article
- Promising Stem Cell therapy in the Management of HIV and AIDS: A Narrative Review.Biologics : targets & therapy · 2022Review
- Biallelic, Selectable, Knock-in Targeting of CCR5Frontiers in immunology · 2022Article
- [Research and Application of Stem Cell-Based Therapy in Idiopathic Pulmonary Fibrosis: A Review].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2021Review
- Targeting CCR5 as a Component of an HIV-1 Therapeutic Strategy.Frontiers in immunology · 2021Review
- Experimental Treatment of SIV-Infected Macaques via Autograft ofMolecular therapy. Methods & clinical development · 2020Article
- Novel Approaches for the Delivery of Anti-HIV Drugs-What Is New?Pharmaceutics · 2019Article
- Organ-on-a-Chip for Cancer and Immune Organs Modeling.Advanced healthcare materials · 2019Review
- Modeling Anti-HIV-1 HSPC-Based Gene Therapy in Humanized Mice Previously Infected with HIV-1.Molecular therapy. Methods & clinical development · 2018Article
- Incorporation of aptamers in the terminal loop of shRNAs yields an effective and novel combinatorial targeting strategy.Nucleic acids research · 2018Article
- The Use of the Humanized Mouse Model in Gene Therapy and Immunotherapy for HIV and Cancer.Frontiers in immunology · 2018Review
- HIV Diagnosis and Treatment through Advanced Technologies.Frontiers in public health · 2017Review
- CRISPR/Cas9 in allergic and immunologic diseases.Expert review of clinical immunology · 2017Article
- A Novel High-Throughput Screening Platform Reveals an Optimized Cytokine Formulation for Human Hematopoietic Progenitor Cell Expansion.Stem cells and development · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
One of the current focuses in HIV/AIDS research is to develop a novel therapeutic strategy that can provide a life-long remission of HIV/AIDS without daily drug treatment and, ultimately, a cure for HIV/AIDS. Hematopoietic stem cell-based anti-HIV gene therapy aims to reconstitute the patient immune system by transplantation of genetically engineered hematopoietic stem cells with anti-HIV genes. Hematopoietic stem cells can self-renew, proliferate and differentiate into mature immune cells. In theory, anti-HIV gene-modified hematopoietic stem cells can continuously provide HIV-resistant immune cells throughout the life of a patient. Therefore, hematopoietic stem cell-based anti-HIV gene therapy has a great potential to provide a life-long remission of HIV/AIDS by a single treatment. Here, we provide a comprehensive review of the recent progress of developing anti-HIV genes, genetic modification of hematopoietic stem progenitor cells, engraftment and reconstitution of anti-HIV gene-modified immune cells, HIV inhibition in in vitro and in vivo animal models, and in human clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.